ArticleClinical epigeneticsPublished
MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer
Regional connection
Verified Author affiliations on the Europe PMC record name Cooper Medical School of Rowan University, Coriell Institute for Medical Research, Lewis Katz School of Medicine, Rowan University, Temple University. Affiliation source
Publication record
- Type
- Article
- Venue
- Clinical epigenetics
- Published
- Topic
- Disease research
- Subject terms
- Cell Line, Tumor; Animals; Humans; Mice; Rats; Apoptosis; DNA Methylation; Cyclin-Dependent Kinase 9; Leukemia, Myeloid, Acute; Decitabine; CDK9; Epigenetic Therapy
- PubMed ID
- 38172923
- PubMed Central ID
- PMC10765884
- Open access
- Yes, open
- Added to directory
- Source checked